Immunoscore As A Predictor Of Disease Recurrences And Patients’ Survival in Colon Cancer : A Clinicopathologic Study.
DOI:
https://doi.org/10.3889/oamjms.2020.3523Keywords:
Colon cancer, Immunoscore, CD8, CD3Abstract
BACKGROUND: For years, the American Joint Committee of Cancer/International Union against Cancer TNM staging system was the only accepted staging system for colorectal cancer. Different studies highlighted limitations in this staging system with the need to another staging approach that takes into consideration the individual patient immune response. Recently, the immunoscore was introduced; however, no accurate data regarding its sensitivity and specificity over the routinely used TNM staging system.
AIM: We aimed to provide definite sensitivity, septicity, and predictive values for both IS and TNM staging system in prognosis prediction, as evidence-based statistical documentation of its validity to clinical use.
METHODS: Fifty-three slides of colon cancer cases were stained for CD3 and CD8 immunohistochemical stains. The density of the stained cells was measured used an image analysis system in the core of the tumor and invasive margin. Immunoscore was calculated and results were compared with TNM in the recurrence-free survival of the patients. The sensitivity and specificity for each test were calculated.
RESULTS: High IS was correlated with a good prognosis in the studied cases. IS sensitivity reached 85.7% compared to 28.6% in TNM staging system and the specificity was 78.1% compared to 37.5% in TNM system.
CONCLUSION: IS is a promising prognostic estimation tool in colon cancer with better sensitivity and specificity than TNM staging system. The routine use of IS is now becoming a mandatory step.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol. 2009;3(2):131-44. PMid:19351284
Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20(7):1891-9. https://doi.org/10.1158/1078-0432. ccr-13-2830 PMid:24691640
Wirta EV, Seppälä T, Friman M, Väyrynen J, Ahtiainen M, Kautiainen H, et al. Immunoscore in mismatch repair-proficient and-deficient colon cancer. J Pathol Clin Res. 2017;3(3):203-13. https://doi.org/10.1002/cjp2.71 PMid:28770104
Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4(5):419-30. https://doi.org/10.1158/2326-6066. cir-15-0110 PMid:26968206
Zeitoun G, Sissy CE, Kirilovsky A, Anitei G, Todosi AM, Marliot F, et al. The Immunoscore in the clinical practice of patients with colon and rectal cancers. Chirurgia. 2019;114(2):152-61. https:// doi.org/10.21614/chirurgia.114.2.152 PMid:31060646
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New strategies in breast cancer: Immunotherapy. Clin Cancer Res. 2016;22(9):2105-10. https://doi.org/10.1158/1078-0432. ccr-15-1315 PMid:26867935
Väyrynen JP, Tuomisto A, Klintrup K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer. 2013;109(7):1839-47. https:// doi.org/10.1038/bjc.2013.508 PMid:24008661
Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the immunoscore: A worldwide task force. J Transl Med. 2012;10:205. PMid:23034130
Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, et al. Strategies for clinical implementation of TNM-immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 2016;27(2):225-32. https://doi.org/10.1093/annonc/mdv560 PMid:26578726
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the “immunoscore” in the classification of malignant tumours. J Pathol. 2014;232(2):199-209. PMid:24122236
Sun R, Nie L, Huang B, Kim DH, Wei L. Quantifying immunoscore performance. Lancet. 2018;392(10158):1624-5. https://doi. org/10.1016/s0140-6736(18)32157-3
Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, et al. Immunoscore signature: A prognostic and predictive tool in gastric cancer. Ann Surg. 2018; 267(3):504-13. PMid:28002059
Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS. Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 2016;7(49):81778-90. https://doi. org/10.18632/oncotarget.13207 PMid:27835889
Edge SB, Compton CC. The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. https:// doi.org/10.1245/s10434-010-0985-4 PMid:20180029
Ikeguchi M, Sakatani T, Endo K, Makino M, Kaibara N. Computerized nuclear morphometry is a useful technique for evaluating the high metastatic potential of colorectal adenocarcinoma. Cancer. 2000;86(10):1944-51. https://doi.org/10.1002/ (sici)1097-0142(19991115)86:10<1944::aid-cncr10>3.0.co;2-2 PMid:10570417
Surve VV, Andersson N, Lehto-Axtelius D, Håkanson R. Comparison of osteopenia after gastrectomy, ovariectomy and prednisolone treatment in the young female rat. Acta Orthop Scand. 2001;72(5):525-32. https://doi. org/10.1080/000164701753532880 PMid:11728082
Zhu Y, Zhang M, Wu X, Bing Z, Wu J, Wang Z, et al. Predictive value of immunoscore in patients with colorectal cancer. Int J Clin Exp Pathol. 2016;9(12):12732-9.
Jorissen RN, Sakthianandeswaren A, Sieber OM. Immunoscore-has it scored for colon cancer precision medicine? Ann Transl Med. 2018;6 Suppl 1:S23. https://doi.org/10.21037/ atm.2018.09.29 PMid:30613598
Sinicrope FA, Shi Q, Hermitte F, Heying EN, Benson AB. Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; alliance). J Clin Oncol. 2018;36(4):614-4. https://doi.org/10.1200/jco.2018.36.4_suppl.614
Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, et al. MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies. Ann Oncol. 2018;29 Suppl 10:493. https://doi.org/10.1093/annonc/mdy493.011
Galon J, Hermitte F, Mlecnik B, Marliot F, Bifulco C, Lugli A, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019;37(4):487-7. https://doi.org/10.1200/ jco.2019.37.4_suppl.487
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet. 2018;391(10135):2128-39. PMid:29754777
Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F. Rational bases for the use of the immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28(8):373-82. https://doi. org/10.1093/intimm/dxw021 PMid:27121213
Yomoda T, Sudo T, Kawahara A, Shigaki T, Shimomura S, Tajiri K, et al. The Immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells. Ann Surg Oncol. 2019;26(2):415- 24. https://doi.org/10.1245/s10434-018-07110-z PMid:30569297
Ogino S, Giannakis M. Immunoscore for (colorectal) cancer precision medicine. Lancet. 2018;391(10135):2084-6. https:// doi.org/10.1016/s0140-6736(18)30953-x PMid:29754776
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Reham Shehab El Nemr Esmail, Dalia Abdel Kareem, Marwa Shabana, Amr Kamal (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
